depression.brivaracetamMonitor Closely (1)brivaracetam and prochlorperazine both increase sedation. Use Caution/Monitor.bromocriptineSerious - Use Alternative (1)prochlorperazine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.brompheniramineMonitor Closely (1)brompheniramine and prochlorperazine both increase sedation. Use Caution/Monitor.buprenorphineMonitor Closely (2)buprenorphine and prochlorperazine both increase sedation. Use Caution/Monitor. buprenorphine and prochlorperazine both decrease QTc interval. Use Caution/Monitor.buprenorphine buccalMonitor Closely (2)buprenorphine buccal and prochlorperazine both increase sedation. Use Caution/Monitor. buprenorphine buccal and prochlorperazine both decrease QTc interval. Use Caution/Monitor.buprenorphine subdermal implantMonitor Closely (1)buprenorphine subdermal implant and prochlorperazine both decrease QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)buprenorphine subdermal implant and prochlorperazine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine transdermalMonitor Closely (1)buprenorphine transdermal and prochlorperazine both decrease QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)buprenorphine transdermal and prochlorperazine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine, long-acting injectionMonitor Closely (2)buprenorphine, long-acting injection and prochlorperazine both decrease QTc interval. Use Caution/Monitor. prochlorperazine increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.Serious - Use Alternative (1)buprenorphine, long-acting injection and prochlorperazine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebupropionMonitor Closely (2)prochlorperazine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible. bupropion will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.butabarbitalMonitor Closely (1)butabarbital and prochlorperazine both increase sedation. Use Caution/Monitor.butalbitalMonitor Closely (1)butalbital and prochlorperazine both increase sedation. Use Caution/Monitor.butorphanolMonitor Closely (1)butorphanol and prochlorperazine both increase sedation. Use Caution/Monitor.cabergolineSerious - Use Alternative (1)prochlorperazine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated.caffeineMonitor Closely (1)prochlorperazine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.calcium/magnesium/potassium/sodium oxybatesSerious - Use Alternative (1)prochlorperazine, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.captoprilMinor (1)prochlorperazine increases effects of captopril by unspecified interaction mechanism. Minor/Significance Unknown.carbinoxamineMonitor Closely (1)carbinoxamine and prochlorperazine both increase sedation. Use Caution/Monitor.carisoprodolMonitor Closely (1)carisoprodol and prochlorperazine both increase sedation. Use Caution/Monitor.celecoxibMinor (1)celecoxib will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.cenobamateMonitor Closely (1)cenobamate, prochlorperazine. Either increases effects of the other by sedation. Use Caution/Monitor.chasteberryMinor (1)chasteberry decreases effects of prochlorperazine by pharmacodynamic antagonism. Minor/Significance Unknown. (Theoretical interaction).chloral hydrateMonitor Closely (1)chloral hydrate and prochlorperazine both increase sedation. Use Caution/Monitor.chlordiazepoxideMonitor Closely (1)chlordiazepoxide and prochlorperazine both increase sedation. Use Caution/Monitor.chloroquineMinor (2)chloroquine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown. chloroquine increases levels of prochlorperazine by decreasing metabolism. Minor/Significance Unknown.chlorpheniramineMonitor Closely (1)chlorpheniramine and prochlorperazine both increase sedation. Use Caution/Monitor.chlorpromazineMonitor Closely (2)chlorpromazine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. chlorpromazine and prochlorperazine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)chlorpromazine and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.chlorzoxazoneMonitor Closely (1)chlorzoxazone and prochlorperazine both increase sedation. Use Caution/Monitor.cigarette smokingMonitor Closely (1)cigarette smoking decreases levels of prochlorperazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine & thioridazine, but may occur w/other phenothiazines.cimetidineMinor (1)cimetidine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.cinnarizineMonitor Closely (1)cinnarizine and prochlorperazine both increase sedation. Use Caution/Monitor.cisatracuriumMonitor Closely (3)cisatracurium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. cisatracurium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.citalopramMonitor Closely (1)citalopram and prochlorperazine both increase serotonin levels. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.clarithromycinSerious - Use Alternative (1)prochlorperazine and clarithromycin both increase QTc interval. Avoid or Use Alternate Drug.clemastineMonitor Closely (1)clemastine and prochlorperazine both increase sedation. Use Caution/Monitor.clobazamMonitor Closely (1)prochlorperazine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).clomipramineMonitor Closely (2)prochlorperazine and clomipramine both increase QTc interval. Use Caution/Monitor. prochlorperazine and clomipramine both increase sedation. Use Caution/Monitor.Minor (2)clomipramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. clomipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.clonazepamMonitor Closely (1)clonazepam and prochlorperazine both increase sedation. Use Caution/Monitor.clonidineMonitor Closely (1)clonidine, prochlorperazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.clorazepateMonitor Closely (1)clorazepate and prochlorperazine both increase sedation. Use Caution/Monitor.clozapineMonitor Closely (2)clozapine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. clozapine and prochlorperazine both increase sedation. Use Caution/Monitor.codeineMonitor Closely (1)codeine and prochlorperazine both increase sedation. Use Caution/Monitor.cyclizineMonitor Closely (4)cyclizine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. cyclizine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of cyclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. cyclizine and prochlorperazine both increase sedation. Use Caution/Monitor.cyclobenzaprineMonitor Closely (4)cyclobenzaprine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. cyclobenzaprine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. cyclobenzaprine and prochlorperazine both increase sedation. Use Caution/Monitor.cyproheptadineMonitor Closely (1)cyproheptadine and prochlorperazine both increase sedation. Use Caution/Monitor.dantroleneMonitor Closely (1)dantrolene and prochlorperazine both increase sedation. Use Caution/Monitor.daridorexantMonitor Closely (1)prochlorperazine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. darifenacinMonitor Closely (3)darifenacin decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. darifenacin decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of darifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.Minor (1)darifenacin will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.dasatinibMonitor Closely (1)prochlorperazine and dasatinib both increase QTc interval. Modify Therapy/Monitor Closely.deferoxamineMonitor Closely (1)deferoxamine, prochlorperazine. Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Synergistic increase in neurological adverse effects.degarelixSerious - Use Alternative (1)degarelix and prochlorperazine both decrease QTc interval. Avoid or Use Alternate Drug.desfluraneMonitor Closely (2)desflurane and prochlorperazine both decrease QTc interval. Use Caution/Monitor. desflurane and prochlorperazine both increase sedation. Use Caution/Monitor.desipramineMonitor Closely (2)prochlorperazine and desipramine both increase QTc interval. Use Caution/Monitor. prochlorperazine and desipramine both increase sedation. Use Caution/Monitor.Minor (2)desipramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. desipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.desvenlafaxineMonitor Closely (1)desvenlafaxine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mgdeutetrabenazineMonitor Closely (2)deutetrabenazine and prochlorperazine both decrease QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation). prochlorperazine and deutetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely. The risk for parkinsonism, neuroleptic malignant syndrome, and akathisia may be increased by concomitant use of deutetrabenazine and dopamine antagonists or antipsychotics.dexchlorpheniramineMonitor Closely (1)dexchlorpheniramine and prochlorperazine both increase sedation. Use Caution/Monitor.dexfenfluramineMonitor Closely (2)prochlorperazine, dexfenfluramine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dexmedetomidineMonitor Closely (1)dexmedetomidine and prochlorperazine both increase sedation. Use Caution/Monitor.dexmethylphenidateMonitor Closely (2)prochlorperazine, dexmethylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextroamphetamineMonitor Closely (2)prochlorperazine, dextroamphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextromoramideMonitor Closely (1)dextromoramide and prochlorperazine both increase sedation. Use Caution/Monitor.diamorphineMonitor Closely (1)diamorphine and prochlorperazine both increase sedation. Use Caution/Monitor.diazepamMonitor Closely (1)diazepam and prochlorperazine both increase sedation. Use Caution/Monitor.dicyclomineMonitor Closely (3)dicyclomine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. dicyclomine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of dicyclomine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.diethylpropionMonitor Closely (2)prochlorperazine, diethylpropion. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.difelikefalinMonitor Closely (1)difelikefalin and prochlorperazine both increase sedation. Use Caution/Monitor.difenoxin hclMonitor Closely (1)difenoxin hcl and prochlorperazine both increase sedation. Use Caution/Monitor.dimenhydrinateMonitor Closely (1)dimenhydrinate and prochlorperazine both increase sedation. Use Caution/Monitor.diphenhydramineMonitor Closely (4)diphenhydramine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. diphenhydramine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. diphenhydramine and prochlorperazine both increase sedation. Use Caution/Monitor.Minor (1)diphenhydramine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.diphenoxylate hclMonitor Closely (1)diphenoxylate hcl and prochlorperazine both increase sedation. Use Caution/Monitor.dipipanoneMonitor Closely (1)dipipanone and prochlorperazine both increase sedation. Use Caution/Monitor.disopyramideContraindicated (1)prochlorperazine and disopyramide both increase QTc interval. Contraindicated.dobutamineMonitor Closely (2)prochlorperazine, dobutamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dofetilideSerious - Use Alternative (1)prochlorperazine and dofetilide both increase QTc interval. Avoid or Use Alternate Drug.dolasetronMonitor Closely (1)prochlorperazine and dolasetron both increase QTc interval. Modify Therapy/Monitor Closely.donepezilMonitor Closely (1)donepezil and prochlorperazine both decrease QTc interval. Use Caution/Monitor.donepezil transdermalMonitor Closely (1)donepezil transdermal, prochlorperazine. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.dopamineMonitor Closely (2)prochlorperazine, dopamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)prochlorperazine decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.dopexamineMonitor Closely (1)prochlorperazine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dosulepinMonitor Closely (1)prochlorperazine and dosulepin both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)prochlorperazine and dosulepin both increase QTc interval. Avoid or Use Alternate Drug.doxepinMonitor Closely (2)prochlorperazine and doxepin both increase QTc interval. Use Caution/Monitor. prochlorperazine and doxepin both increase sedation. Use Caution/Monitor.Minor (2)doxepin, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. doxepin, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.doxylamineMonitor Closely (1)doxylamine and prochlorperazine both increase sedation. Use Caution/Monitor.dronedaroneSerious - Use Alternative (1)prochlorperazine and dronedarone both increase QTc interval. Avoid or Use Alternate Drug.Minor (1)dronedarone will increase the